JBIO Stock — Jade Biosciences Inc.: Cash, EV, Pipeline

Share price

$16.94

Market cap

$1,077.3M

Cash

$461.2M

Enterprise value

$616.1M

Balance sheet

Cash	$461.2M
Debt	$0.0M
Net cash	$461.2M
Enterprise value	$616.1M
Basic shares	63.6M shares
Fully diluted shares	97.9M shares
Fully diluted market cap	$1,658.5M
Cash per share	$7.25

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading JBIO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 12 - Dec 24	JADE101	Phase 1	Healthy Volunteers	—
Jun 12 - Jul 24	JADE101	Phase 1	Healthy Volunteers (HV)	—
Nov 12 - Dec 24	JADE201	Phase 1	Rhematoid Arthritis	—
Feb 12 - Mar 26	JADE101	Phase 2	IgA Nephropathy	2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

JADE101

Phase 2 · Active Modality: monoclonal antibody

Target APRIL

Partnerships Paragon Therapeutics (worldwide exclusive license; up to $22.0M development/regulatory milestones plus low-to-mid single-digit royalties)

Indications

IgA nephropathy (IgAN) (Phase 2)

Catalysts

— None
— None

Status note Anti-APRIL monoclonal antibody initially in IgA nephropathy. JUNIPER open-label Phase 2 study in IgAN patients dosed first patient May 2026. Phase 1 in healthy volunteers initiated Aug 2025.

JADE201

Phase 1 · Active Modality: monoclonal antibody

Target BAFF-R

Partnerships Paragon Therapeutics (worldwide exclusive license; up to $22.0M milestones plus low-to-mid single-digit royalties)

Indications

Rheumatoid arthritis (Phase 1)

Catalysts

— None

Status note Anti-BAFF-R monoclonal antibody. Phase 1 trial in patients with rheumatoid arthritis dosed first patient May 2026.

JADE301

Preclinical · Active Modality: monoclonal antibody

Aliases JADE-003

Target IFN-beta

Partnerships Paragon Therapeutics (worldwide exclusive license; up to $22.0M milestones plus low-to-mid single-digit royalties)

Indications

Dermatomyositis (Preclinical)

Catalysts

— None
— None

Status note Anti-IFN-beta monoclonal antibody initially in dermatomyositis. Development candidate selected Dec 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	JADE101
Lead indication	IgA Nephropathy
Lead phase	Phase 2
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07541287	Phase 2	Recruiting	Sponsor	JBIO	—	IgA Nephropathy	2027
NCT07059312	Phase 1	Active, not recruiting	Sponsor	JBIO	—	Healthy Volunteers	—
NCT07525947	Phase 1	Recruiting	Sponsor	JBIO	—	Healthy Volunteers (HV)	—
NCT07533955	Phase 1	Recruiting	Sponsor	JBIO	—	Rhematoid Arthritis	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Jade Biosciences, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	1,230,426	-410,711	0.14%	2026-08-14
Logos Global Management	1,125,000	+725,000	1.08%	2026-08-14
Ikarian Capital	427,349	-85,000	1.55%	2026-08-14
RTW Investments	0	-573,205	0.00%	2026-08-14
OrbiMed Advisors	0	-185,011	0.00%	2026-08-14
ADAR1 Capital Management	0	-20,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

JBIO — Jade Biosciences Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders